Target Product Profiles 2008: Physician Insights on Key Attributes - Colon Cancer (Stage III) - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/604255

Target Product Profiles 2008: Physician Insights on Key Attributes - Colon Cancer (Stage III)

Description:

A therapy that improves disease-free survival over FOLFOX4 at three years for the treatment of stage III colon cancer.

Using Target Product Profiles in Your Market Strategy
Our Target Product Profiles qualitatively predict the market potential of a drug fulfilling a key unmet need. This information is critical for evaluating the impact of clinical attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor’s. Examples of how to
use the information you will f nd in this report are highlighted below:

- For companies who are developing a drug with some of the characteristics we are testing, our survey results reveal the standards that surveyed physicians expect the remainder of the drug’s clinical profi le to meet. Our analysis begins to uncover physician-expected drug attributes as well as acceptable trade-offs in emerging therapies. Our primary research with practicing physicians includes this emerging therapy’s anticipated patient share, projected use by line of therapy, and forecasted sales.
- For companies that already have a drug launched for the indication in question, our data and analysis show the impact an emerging drug would have on their brand’s market. Not only does our research reveal which existing brands would be replaced by a drug meeting the Target Product Profile le, but it also clearly outlines whether any drugs in the pipeline will meet the criteria laid out by physicians to challenge the existing sales leader. This knowledge gives existing brands the information they need to protect their share, either through new clinical trials aimed at end points physicians say are critical differentiators or by aggressive marketing of brand attributes that emerging agents will not be able to beat.
- For companies looking to enter a disease through licensing or acquisition, the challenge of sifting through tens or hundreds of early-stage candidates can be daunting. Our Target Product Profiles can quickly show business development teams the clinical attributes that are unique versus products already on the market, and our primary research with physicians quickly identifies likely share and market potential to give a first glimpse at valuation.

Because all of our Target Product Profiles are designed to be attainable within the next decade, our research can be a fast and efficient way to whittle the field of potential licensing candidates down to the most valuable few.

Report Contents
The Target Product Profile le reports are divided into two sections. The first section, “Etiology and Pathophysiology,” offers a high-level view of the genetic and environmental causes of the disease under study, as well as the subsequent symptoms and clinical effects that result. This section is intended to give the reader a clear view of the physical and biochemical pathways that are known, or suspected, to be causative to disease onset or progression. These pathways, therefore, are common targets for drug therapy; where possible, we identify the molecular targets against which current or emerging drugs act.

The second section, “Target Product Profile le Summary,” begins with an overview of the drug development landscape and the attributes on which investigators are focusing. Based on this analysis, as well as the clinical end points that practicing physicians say are most influential in their prescribing decision, our analysts define a key unmet need that could be addressed within the next ten years. Our Target Product Profile les are a set of quantified ed performance measures against key clinical end points and attributes that physicians build themselves. Our analysis of physician-desired attributes identifies areas of potential trade-offs versus those attributes that are either expected in new agents or are fully satisfied ed by current therapies. This section concludes with an analysis of high profile agents currently in the pipeline (“Competitors to Watch” and “Emerging Product Profiles”).

Using surveyed physicians’ estimates of these agents’ usage as inputs, our analysis integrates our extensive knowledge of the competitive landscape and non-clinical market hurdles to determine the market potential of these agents and their threat to current brands.

Contents:

Introduction

Using Target Product Profiles in Your Market Strategy
Report Contents
Target Product Profile Methodology

Etiology and Pathophysiology

Overview
Anatomy
Pathophysiology
Signs and Symptoms
Staging Prognosis
Metastasis
Patterns of Recurrent Disease
Etiology
Colorectal Tumorigenesis Pathways
Genetic Changes
Role of Epidermal Growth Factor Receptor
Role of Insulin-Like Growth Factor
Risk Factors

Target Product Profile Discussion—Stage III Colon Cancer

Target Product Profile Summary for Stage III Colon Cancer—2011
Assessing Drug Development Opportunities
Physician Survey Results
Efficacy
Safety and Tolerability
Delivery
Estimated Patient Share
Pricing Potential
Forecasted 2016 Pricing Environment
Competitors to Watch
Emerging Product Profiles

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/604255

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 02/12/2008 06:57:08

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Target Product Profiles 2008: Physician Insights on Key Attributes - Colon Cancer (Stage III)
Web Address:
http://www.researchandmarkets.com/reports/604255
Office Code:
OCIFGMLRNQX

Report formats

Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€5,954.00

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 02/12/2008 06:57:08

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World